Condition: Breast Cancer · Prostate Cancer · Sponsor: University of Virginia
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.
This description comes directly from the study's public registry record.
Ashley Lamont · (434) 243-6377 · ZWZ6JM@uvahealth.org
Laura Livingston · 434-882-5578 · LL9TE@uvahealth.org
Always discuss trial participation with your own doctor first.
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07441889